Biosimilar uptake appears to finally be on the upswing, and Biocon Biologics is betting on the sector’s future

When a copycat of Amgen’s Neupogen became the first approved biosimilar in the U.S. less than a decade ago, the competitive prospect of drugs that mimicked pricey biologics appeared poised to bring down drug costs.

Now, biosimilar makers are still fighting for even small slices of the patient population as the makers of branded drugs rake in the profits.